REG - Kromek Group PLC - Kromek receives £1.4m CBRN order for EU stockpile

KromekAnnouncement

25/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240125:nRSY8960Aa&default-theme=true

RNS Number : 8960A  Kromek Group PLC  25 January 2024

25 January 2024

Kromek Group plc

("Kromek" or the "Group")

 

Kromek receives £1.4m order to deliver D3M detectors for use in EU Stockpile

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments, announces that it has received an order in excess of £1.4m to
supply D3M detectors and associated networkable solutions. The revenues are
expected to be received within the current financial year.

 

The detectors are intended for use in the rescEU stockpile, which is being
developed by the European Commission to help safeguard citizens from disasters
and manage emerging risks, including equipment to respond to chemical,
biological, radiological, and nuclear (CBRN) risks. The order is fully funded
by the EU, through the Directorate-General for European Civil Protection and
Humanitarian Aid Operations.

 

Arnab Basu, CEO of Kromek, said: "Amid increasingly fraught and volatile
global relations, the need for sovereign nations to prepare for emerging risks
has never been more important.

 

"We are pleased to be able to contribute positively to global efforts to
safeguard citizens against possible threats, accidental or deliberate.

 

"This latest order for Kromek's D3M line of detectors is another endorsement
of our world-leading technology, which is amongst the most versatile and
sensitive available, offering real time data of any potential nuclear threat
so that decision making can be rapid and responses can be co-ordinated
effectively."

 

 

 For further information, please contact:

  

Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Paul Farquhar, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Tim Redfern - ECM

 Michael Johnson/Tamar Cranford-Smith - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQELBLZFLFBBZ